{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:16:33Z","timestamp":1793744193705,"version":"4.6.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.xcrm.2025.102078","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T10:38:41Z","timestamp":1744627121000},"page":"102078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Tailoring an intravenously injectable oncolytic virus for augmenting radiotherapy"],"prefix":"10.1016","volume":"6","author":[{"given":"Chen","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangna","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaohe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangjun","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keman","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4762-8279","authenticated-orcid":false,"given":"Funan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.102078_bib1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2025.102078_bib2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic Viruses in Cancer Treatment: A Review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2025.102078_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2025.102078_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28729","article-title":"Application of oncolytic virus in tumor therapy","volume":"95","author":"Huang","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.xcrm.2025.102078_bib5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.radonc.2011.05.078","article-title":"Oncolytic viruses in radiation oncology","volume":"99","author":"Touchefeu","year":"2011","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.xcrm.2025.102078_bib6","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMoa2202028","article-title":"Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma","volume":"386","author":"G\u00e1llego P\u00e9rez-Larraya","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102078_bib7","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.102078_bib8","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u0394 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2025.102078_bib9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","article-title":"Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial","volume":"22","author":"Fares","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102078_bib10","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/1078-0432.CCR-21-3324","article-title":"Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies","volume":"28","author":"van Putten","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102078_bib11","doi-asserted-by":"crossref","first-page":"757","DOI":"10.3171\/2021.3.JNS203045","article-title":"Characterization of patient-derived bone marrow human mesenchymal stem cells as oncolytic virus carriers for the treatment of glioblastoma","volume":"136","author":"Shimizu","year":"2022","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.xcrm.2025.102078_bib12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2021.04.043","article-title":"Phase I dose-escalation study of endoscopic intratumoral injection of OBP-301 (Telomelysin) with radiotherapy in oesophageal cancer patients unfit for standard treatments","volume":"153","author":"Shirakawa","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2025.102078_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003119","article-title":"Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB\/II trial","volume":"9","author":"Monga","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102078_bib14","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-22-0622","article-title":"A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer","volume":"28","author":"Sun","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102078_bib15","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/neuonc\/noy202","article-title":"Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma","volume":"21","author":"Kieran","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.xcrm.2025.102078_bib16","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.bjps.2020.05.009","article-title":"Phase 1 Lymfactin(\u24c7) Study: Short-term Safety of Combined Adenoviral VEGF-C and Lymph Node Transfer Treatment for Upper Extremity Lymphedema","volume":"73","author":"Hartiala","year":"2020","journal-title":"J. Plast. Reconstr. Aesthet. Surg."},{"key":"10.1016\/j.xcrm.2025.102078_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002374","article-title":"Phase I study of a multitargeted recombinant Ad5 PSA\/MUC-1\/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Bilusic","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2025.102078_bib18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/ijgc-2022-003914","article-title":"Intratumoral injection of oncolytic virus (H101) in combination with concurrent chemoradiotherapy for locally advanced cervical cancer","volume":"33","author":"Zhang","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.xcrm.2025.102078_bib19","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.xcrm.2025.102078_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2023.102930","article-title":"Advanced liposome and polymersome-based drug delivery systems: Considerations for physicochemical properties, targeting strategies and stimuli-sensitive approaches","volume":"317","author":"Kans\u0131z","year":"2023","journal-title":"Adv. Colloid Interface Sci."},{"key":"10.1016\/j.xcrm.2025.102078_bib21","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1016\/j.biomaterials.2014.03.060","article-title":"Enhanced therapeutic efficacy of an adenovirus-PEI-bile-acid complex in tumors with low coxsackie and adenovirus receptor expression","volume":"35","author":"Lee","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.xcrm.2025.102078_bib22","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1021\/acs.biomac.5b00538","article-title":"Oncolytic Adenovirus Coated with Multidegradable Bioreducible Core-Cross-Linked Polyethylenimine for Cancer Gene Therapy","volume":"16","author":"Choi","year":"2015","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.xcrm.2025.102078_bib23","doi-asserted-by":"crossref","first-page":"8166","DOI":"10.1039\/D2TB01358D","article-title":"Polyethyleneimine-based immunoadjuvants for designing cancer vaccines","volume":"10","author":"Yang","year":"2022","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.xcrm.2025.102078_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/mabi.202300188","article-title":"Hyperbranched Polymer-Based Vaccines for Cancer Immunotherapy","volume":"23","author":"Wang","year":"2023","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.xcrm.2025.102078_bib25","article-title":"Oncolytic Virus-Driven Biotherapies from Bench to Bedside","volume":"19","author":"Duan","year":"2023","journal-title":"Small"},{"key":"10.1016\/j.xcrm.2025.102078_bib26","first-page":"830","article-title":"Progress in oncolytic viruses modified with nanomaterials for intravenous application","volume":"20","author":"Chen","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.xcrm.2025.102078_bib27","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.coviro.2016.08.007","article-title":"Retargeting of herpes simplex virus (HSV) vectors","volume":"21","author":"Goins","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.xcrm.2025.102078_bib28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jconrel.2017.01.048","article-title":"Cell-mediated delivery of synthetic nano- and microparticles","volume":"259","author":"Ayer","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.xcrm.2025.102078_bib29","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1002\/anie.201907484","article-title":"Polymer Nanocontainers for Intracellular Delivery","volume":"59","author":"Pottanam Chali","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.xcrm.2025.102078_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113851","article-title":"Liposome composition in drug delivery design, synthesis, characterization, and clinical application","volume":"176","author":"Large","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.xcrm.2025.102078_bib31","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.biomaterials.2010.10.031","article-title":"Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.xcrm.2025.102078_bib32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17425247.2019.1617269","article-title":"Achieving systemic delivery of oncolytic viruses","volume":"16","author":"Hill","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.xcrm.2025.102078_bib33","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1007\/s12274-021-4031-6","article-title":"Emerging systemic delivery strategies of oncolytic viruses: A key step toward cancer immunotherapy","volume":"15","author":"Ban","year":"2022","journal-title":"Nano Res."},{"key":"10.1016\/j.xcrm.2025.102078_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202202278","article-title":"Emerging Magnetic Fabrication Technologies Provide Controllable Hierarchically-Structured Biomaterials and Stimulus Response for Biomedical Applications","volume":"9","author":"Wychowaniec","year":"2022","journal-title":"Adv. Sci."},{"key":"10.1016\/j.xcrm.2025.102078_bib35","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cell.2020.02.001","article-title":"Targeting Strategies for Tissue-Specific Drug Delivery","volume":"181","author":"Zhao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2025.102078_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/smtd.202301131","article-title":"Stimuli-Responsive Nanoradiosensitizers for Enhanced Cancer Radiotherapy","volume":"8","author":"Xiao","year":"2024","journal-title":"Small Methods"},{"key":"10.1016\/j.xcrm.2025.102078_bib37","article-title":"Reactive oxygen species-responsive polymer drug delivery systems","volume":"11","author":"Liu","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.xcrm.2025.102078_bib38","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1021\/ja908124g","article-title":"Dual redox responsive assemblies formed from diselenide block copolymers","volume":"132","author":"Ma","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.xcrm.2025.102078_bib39","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2025.102078_bib40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.it.2022.01.006","article-title":"Lighting up the tumor fire with low-dose irradiation","volume":"43","author":"Herrera","year":"2022","journal-title":"Trends Immunol."},{"key":"10.1016\/j.xcrm.2025.102078_bib41","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2025.102078_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/neup.12764","article-title":"LINC01123 potentially correlates with radioresistance in glioma through the miR-151a\/CENPB axis","volume":"42","author":"Tian","year":"2022","journal-title":"Neuropathology"},{"key":"10.1016\/j.xcrm.2025.102078_bib43","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12929-019-0510-4","article-title":"SOX17 overexpression sensitizes chemoradiation response in esophageal cancer by transcriptional down-regulation of DNA repair and damage response genes","volume":"26","author":"Kuo","year":"2019","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.xcrm.2025.102078_bib44","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1007\/s12094-023-03169-7","article-title":"The development of radioresistant oral squamous carcinoma cell lines and identification of radiotherapy-related biomarkers","volume":"25","author":"Huang","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.xcrm.2025.102078_bib45","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ygeno.2011.01.005","article-title":"Differential expression of immune-associated cancer regulatory genes in low- versus high-dose-rate irradiated AKR\/J mice","volume":"97","author":"Shin","year":"2011","journal-title":"Genomics"},{"key":"10.1016\/j.xcrm.2025.102078_bib46","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/annonc\/mdt385","article-title":"Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma","volume":"25","author":"Ponzoni","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.xcrm.2025.102078_bib47","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1158\/1535-7163.MCT-17-0480","article-title":"Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma","volume":"17","author":"Narayan","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2025.102078_bib48","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.7150\/thno.78091","article-title":"Human papillomavirus E6\/E7 oncoproteins promote radiotherapy-mediated tumor suppression by globally hijacking host DNA damage repair","volume":"13","author":"Bruyere","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.xcrm.2025.102078_bib49","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.7150\/thno.21451","article-title":"Targeting CPT1A-mediated fatty acid oxidation sensitizes nasopharyngeal carcinoma to radiation therapy","volume":"8","author":"Tan","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.xcrm.2025.102078_bib50","article-title":"Tescalcin\/c-Src\/IGF1R\u03b2-mediated STAT3 activation enhances cancer stemness and radioresistant properties through ALDH1","volume":"8","author":"Lee","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.xcrm.2025.102078_bib51","doi-asserted-by":"crossref","DOI":"10.1172\/JCI156305","article-title":"A p300\/GATA6 axis determines differentiation and Wnt dependency in pancreatic cancer models","volume":"132","author":"Zhong","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102078_bib52","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11060-022-03996-8","article-title":"Diaph3 underlines tumor cell heterogeneity in glioblastoma with implications for treatment modalities resistance","volume":"157","author":"Stoyanov","year":"2022","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.xcrm.2025.102078_bib53","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3892\/ijo.2014.2260","article-title":"Intensity modulated radiotherapy induces pro-inflammatory and pro-survival responses in prostate cancer patients","volume":"44","author":"El-Saghire","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.xcrm.2025.102078_bib54","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/s41418-022-01011-1","article-title":"A viral interferon regulatory factor degrades RNA-binding protein hnRNP Q1 to enhance aerobic glycolysis via recruiting E3 ubiquitin ligase KLHL3 and decaying GDPD1 mRNA","volume":"29","author":"Qi","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.xcrm.2025.102078_bib55","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jtho.2018.01.028","article-title":"Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy","volume":"13","author":"Wen","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.xcrm.2025.102078_bib56","doi-asserted-by":"crossref","first-page":"20511","DOI":"10.1073\/pnas.1906578116","article-title":"CRIF1 as a potential target to improve the radiosensitivity of osteosarcoma","volume":"116","author":"Ran","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2025.102078_bib57","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41422-019-0263-3","article-title":"The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression","volume":"30","author":"Lei","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.xcrm.2025.102078_bib58","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1158\/1078-0432.CCR-20-3358","article-title":"The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors","volume":"27","author":"van Bijsterveldt","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102078_bib59","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.xcrm.2025.102078_bib60","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1172\/JCI43976","article-title":"Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells","volume":"121","author":"Connell","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2025.102078_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112521","article-title":"Critical role of checkpoint kinase 1 in spinal cord injury-induced motor dysfunction in mice","volume":"138","author":"Fan","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.xcrm.2025.102078_bib62","doi-asserted-by":"crossref","first-page":"8431","DOI":"10.1158\/1078-0432.CCR-05-1085","article-title":"Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability","volume":"11","author":"Zhou","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2025.102078_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.dnarep.2021.103115","article-title":"The molecular mechanism of nuclear signaling for degradation of cytoplasmic DNA: Importance in DNA damage response and cancer","volume":"103","author":"Mohammadi","year":"2021","journal-title":"DNA Repair"},{"key":"10.1016\/j.xcrm.2025.102078_bib64","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.pharmthera.2013.12.010","article-title":"Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors","volume":"142","author":"Pitts","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2025.102078_bib65","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102078_bib66","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMra1608986","article-title":"Recent Developments in Radiotherapy","volume":"377","author":"Citrin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2025.102078_bib67","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2025.102078_bib68","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s41417-022-00469-y","article-title":"Challenges and progress toward tumor-targeted therapy by systemic delivery of polymer-complexed oncolytic adenoviruses","volume":"29","author":"Thambi","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.xcrm.2025.102078_bib69","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.addr.2015.09.012","article-title":"PEGylation as a strategy for improving nanoparticle-based drug and gene delivery","volume":"99","author":"Suk","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.xcrm.2025.102078_bib70","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0959-437X(01)00270-2","article-title":"p38 and Chk1 kinases: different conductors for the G(2)\/M checkpoint symphony","volume":"12","author":"Bulavin","year":"2002","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.xcrm.2025.102078_bib71","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.277.5331.1497","article-title":"Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25","volume":"277","author":"Sanchez","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2025.102078_bib72","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/13543784.2019.1694661","article-title":"Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer","volume":"28","author":"Dent","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.xcrm.2025.102078_bib73","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.ctrv.2012.10.007","article-title":"Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy","volume":"39","author":"Maugeri-Sacc\u00e0","year":"2013","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.xcrm.2025.102078_bib74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2013.10.005","article-title":"CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy","volume":"142","author":"McNeely","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.xcrm.2025.102078_bib75","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized cancer immunotherapy","volume":"16","author":"Kuai","year":"2017","journal-title":"Nat. Mater."},{"key":"10.1016\/j.xcrm.2025.102078_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2023.101922","article-title":"Antigen-capturing oncolytic adenoviruses along with IDO blockade for improved tumor immunotherapy","volume":"51","author":"Xu","year":"2023","journal-title":"Nano Today"},{"key":"10.1016\/j.xcrm.2025.102078_bib77","doi-asserted-by":"crossref","first-page":"13207","DOI":"10.1128\/JVI.78.23.13207-13215.2004","article-title":"Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5","volume":"78","author":"Holterman","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.xcrm.2025.102078_bib78","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ymthe.2022.11.016","article-title":"Modification of the Early Gene Enhancer-promoter Improves the Oncolytic Potency of Adenovirus 11","volume":"31","author":"Wong","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2025.102078_bib79","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s004110050106","article-title":"Radioresistant cell strain of human fibrosarcoma cells obtained after long-term exposure to x-rays","volume":"37","author":"Wei","year":"1998","journal-title":"Radiat. Environ. Biophys."},{"key":"10.1016\/j.xcrm.2025.102078_bib80","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1667\/0033-7587(2001)156[0739:TGACOA]2.0.CO;2","article-title":"The generation and characterization of a radiation-resistant model system to study radioresistance in human breast cancer cells","volume":"156","author":"Pearce","year":"2001","journal-title":"Radiat. Res."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912500151X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912500151X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T01:23:08Z","timestamp":1757726588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266637912500151X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S266637912500151X"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102078","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tailoring an intravenously injectable oncolytic virus for augmenting radiotherapy","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.102078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102078"}}